• 德晋贵宾厅

    开放合作的资产

    自身免疫性疾病资产

    自身免疫性疾病是继心血管疾病和癌症之后，全球第三大类疾病。全球自身免疫疾病药物市场规模超过1000亿美元。尽管诊断和治疗的及时性越来越受到重视，但临床上仍存在大量未满足的需求。新靶点药物市场预计将持续扩大，其市场份额有望显著提升。

    在此页面上

    • 德晋贵宾厅自身免疫性疾病相关抗体资产
    • 开放合作的自身免疫性疾病抗体项目
    • 部分资产概览

    网络研讨会

    查看全部

      海报

      查看全部
        为什么选择德晋贵宾厅的自身免疫性疾病相关抗体资产？
        • 我们专有的全人抗体RenMice平台中拥有100多个自免类抗体项目
        • 我们的平台包括RenMab、RenLite和RenNano，适用于开发具有高亲和力和强效阻断活性的单克隆抗体（mAbs）、双特异性抗体（bsAbs）、双特异性抗体药物偶联物（bsADCs）及VHH抗体
        • 现成的治疗性抗体可用于多种适应症，包括哮喘、银屑病、移植物排斥、特应性皮炎、系统性红斑狼疮和类风湿关节炎
        • 我们提供多种合作模式，包括抗体授权、转让及联合开发，并已与众多行业领先企业建立合作关系。欢迎与我们携手合作，共同为全球自身免疫疾病患者带来改变！
        开放合作的自身免疫性疾病抗体项目
        Target(s) Format Immune mice Indication Development Stage
        CD40 mAb RenMab Graft rejection Preclinical
        IL4RA mAb RenMab KO Asthma Candidates Selection
        0X40 BpAb RenLite KO Atopic dermatitis Candidates Selection
        ST2 mAb RenMab KO Asthma, Chronic Obstructive Pulmonary Disease (COPD) Candidates Selection
        TNFSF15 (TL1A) mAb RenMab KO Enteritis Candidates Selection
        0X40 mAb RenMab KO Atopic dermatitis Leads Selection
        0X40L mAb RenMab KO, RenLite Atopic dermatitis Leads Selection
        FCER1 mAb RenMab KO Asthma Leads Selection
        IGHE mAb RenMab KO Asthma, Allergy, Allergic rhinitis Leads Selection
        IL23R mAb RenMab KO Psoriasis,Enteritis Leads Selection
        1L2RB mAb RenMab,RenMab KO Vitiligo, Alopecia areata, Graft rejection Leads Selection
        IL36R mAb RenMab KO Psoriasis Leads Selection
        OSM mAb RenMab KO Osteoporosis.Peripheral neuropathy Leads Selection
        OSMR mAb RenMab KO Pruritus, atopic dermatitis, nodular pruritus, inflammatory bowel disease, pulmonary fibrosis,liver fibrosis Leads Selection
        CXCL13 mAb RenMab,RenMab KO Autoimmune disease Leads Selection
        BAFF mAb RenMab KO Systemic lupus erythematosus (SLE), lgA nephropathy, Sjögren's syndrome, rheumatoid arthritis Hits Selection
        CCR9 mAb RenLite KO Inflammatory Bowel Disease Hits Selection
        CD6 mAb RenMab KO Psoriasis Hits Selection
        CD83 mAb RenMab KO Graft versus host disease, inflammatory disease, Transplant rejection Hits Selection
        DC-SIGN mAb RenMab KO Systemic lupus erythematosus Hits Selection
        FCGR2A mAb RenMab KO Asthma Hits Selection
        FCRN mAb RenMab KO Myasthenia gravis,thrombocytopenia Hits Selection
        IFNAR1 mAb RenMab KO Chronic inflammation Hits Selection
        IL13 mAb RenLite Asthma Hits Selection
        IL17RB mAb RenMab KO Psoriasis Hits Selection
        IL25 mAb RenMab KO Asthma Hits Selection
        IL31 mAb RenMab KO Atopic dermatitis Hits Selection
        IL4 mAb RenMab Asthma Hits Selection
        IL5R mAb RenMab KO Asthma Hits Selection
        IL7RA mAb RenMab KO Graft rejection, Allergic disease, Blood tumor Hits Selection
        ITGB7 mAb RenMab KO DSS induces enteritis Hits Selection
        KIT mAb RenMab Hematopoietic stem cell transplantation, Chronic granulomatous disease, AML. GIST Hits Selection
        MADCAM1 mAb RenMab KO Inflammatory Bowel Disease Hits Selection
        MDL-1 mAb RenMab KO Inflammatory bowel Disease Hits Selection
        TSLP mAb RenMab, RenMab KO Asthma, Atopic Dermatitis, chronic Obstructive Pulmonary Diseases (COPD) Hits Selection

        除以上项目，我们还有更多相关抗体在开发中，敬请关注最新动态！

        部分资产概览

        随时联系我们，探索评估/许可/共同开发机会！

        来自RenMab KO平台的ST2单抗
        资产亮点：
        • 两组克隆分别结合于不同的表位区域，展现出高亲和力，并在人和猴之间具有良好的交叉反应性
        • 在体外实验中抑制IL-33信号通路